ORIC — ORIC Pharmaceuticals, Inc. stock price, charts and financials

QT83ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
13.21
-0.29-2.13%
OverviewShort InterestFilings
ORICQT83ORIC Pharmaceuticals, Inc.·NASDAQ
13.21-2.13%
News
Down 2.1% — ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (globenewswire.com).
Medium confidence
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
AUPH-2.33%$15.48MESO+4.96%$16.73ZBIO-1.46%$31.96GHRS-2.07%$29.64TSHA-0.69%$6.51STOK-1.46%$32.23ABCL+31.03%$9.08VRDN-2.29%$23.05
Snapshot
Index-P/E-EPS (ttm)-Insider Own18.44%Shs Outstand103.52MPerf Week21.95%
Market Cap1.40BForward P/E-EPS next Y-1.64Insider Trans-0.34%Shs Float48.71MPerf Month23.40%
Enterprise Value1.36BPEG-EPS next Q-Inst Own-Short Float45.28%Perf Quarter53.23%
Income-134.58MP/S0.00EPS this Y-Inst Trans-Short Ratio13.63Perf Half Y35.54%
Sales0.00P/B3.82EPS next Y-9.49%ROA-34.68%Short Interest22.05MPerf YTD65.04%
Book/sh-P/C-EPS next 5Y-ROE-35.35%52W High14.61 -9.58%Perf Year36.64%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-40.32%52W Low7.08 86.72%Perf 3Y70.89%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin0.00%Volatility11.38% 7.91%Perf 5Y-18.92%
Dividend TTM-EV/Sales0.00EPS Y/Y TTM21.31%Oper. Margin0.00%ATR (14)0.91Perf 10Y-
Dividend Ex-Date-Quick Ratio13.19Sales Y/Y TTM-Profit Margin0.00%RSI (14)66.39Recom2.00
Dividend Gr. 3/5Y-Current Ratio13.19EPS Q/Q19.05%SMA2017.42%Beta0.95Target Price18.33
Payout0.00%Debt/Eq0.01Sales Q/Q-SMA5033.92%Rel Volume0.74Prev Close13.50
Employees104LT Debt/Eq0.02EarningsNov 12SMA20027.74%Avg Volume1.74MPrice13.21
IPO DateApr 24, 2020Option/ShortYes / YesEPS/Sales Surpr.-6.00% -Net Debt/EBITDA0.24Volume1,285,023Change-2.13%
Analyst Ratings
DateActionAnalystRatingTarget
May-15-26ReiteratedGoldman Sachs$15
Feb-24-26ReiteratedOppenheimerOutperform$12 → $15
Feb-24-26ReiteratedHC Wainwright & Co.Buy$23 → $25
Jan-07-26InitiatedPiper SandlerOverweight$22
Dec-08-25ReiteratedWells FargoOverweight$25
Nov-14-25ReiteratedHC Wainwright & Co.Buy$21 → $23
Sep-04-25ReiteratedGuggenheimBuy$18
May-06-25ReiteratedOppenheimerOutperform$17 → $12
Sep-05-24InitiatedStifelBuy$20
Mar-21-24ReiteratedHC Wainwright & Co.Buy$21
Latest News
Aug-07-26
Aug-07-2604:30PM
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)globenewswire.com
Aug-03-26
Aug-03-2604:57PM
ORIC Pharmaceuticals Q2 EPS $(0.38) Misses $(0.36) EstimateBenzinga
04:05PM
ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updatesglobenewswire.com
Jul-24-26
Jul-24-2601:05PM
12 Health Care Stocks Moving In Friday's Intraday SessionBenzinga
Jul-21-26
Jul-21-2610:30AM
ORIC Pharmaceuticals: Royalty-Free Phase 3 Economics Strengthen The Bull Caseseekingalpha.com
Jul-20-26
Jul-20-2608:30AM
ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026globenewswire.com
Jul-14-26
Jul-14-2604:07PM
ORIC®Pharmaceuticals Initiates Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat In Combination With NUBEQABenzinga
04:05PM
ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayerglobenewswire.com
Jul-02-26
Jul-02-2604:30PM
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)globenewswire.com
Jun-15-26
Jun-15-2608:01AM
Bandwidth, Traws Pharma And Other Big Stocks Moving Lower In Monday's Pre-Market SessionBenzinga
Company

ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
FY 2017
12/31/2017
Total Revenue
000——————
Cost of Goods Sold Incl. D&A111——————
Gross Profit-1-1-1——————
Selling, General and Administrative Excl. Other332926——————
Research and Development11011485——————
Other Operating Expense-1-1-1——————
Operating Income-143-143-111——————
Interest Expense
000——————
Unusual Expense
—————————
Non-Operating Income (Expense)141510——————
Net Income Before Taxes-129-128-101——————
Income Taxes
000——————
Consolidated Net Income-129-128-101——————
Net Income From Continuing Operations-129-128-101——————
Net Income-129-128-101——————
EPS (Recurring)-1.47-1.83-1.96——————
EPS (Basic, Before Extraordinaries)-1.47-1.83-1.96——————
EPS (Diluted)-1.47-1.83-1.96——————
EBITDA-128-127-100——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio
—————————
Gross Margin
—————————
Operating Margin
—————————
Net Margin
—————————
Shares Outstanding887051——————
Market Capitalization720565469——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$15.45$13.20$10.95$8.69$6.44● Close Price0.00M0.44M0.88M1.32M1.76MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Heyman Richard A.DirectorJul 24 '26Sale12.0213,100157,46238,300Jul 28
Heyman Richard A.DirectorJul 24 '26Option Exercise1.603,5005,60045,300Jul 28
Heyman Richard A.DirectorJul 06 '26Sale12.003003,600212,772Jul 08
Piscitelli DominicChief Financial OfficerFeb 24 '26Option Exercise4.3652,000226,720120,148Feb 26
Piscitelli DominicChief Financial OfficerFeb 24 '26Sale13.5152,000702,68668,148Feb 26
Heyman Richard A.DirectorJan 16 '26Sale12.006,70080,43141,800Jan 20
Multani Pratik SChief Medical OfficerDec 16 '25Sale9.0610,72097,12968,149Dec 17
Piscitelli DominicChief Financial OfficerDec 16 '25Sale9.0610,72097,12768,148Dec 17
Chacko JacobPRESIDENT AND CEODec 16 '25Sale9.0633,374302,368581,711Dec 17
Multani Pratik SChief Medical OfficerDec 15 '25Option Exercise0.0058,666078,869Dec 17
Piscitelli DominicChief Financial OfficerDec 15 '25Option Exercise0.0058,666078,868Dec 17
Chacko JacobPRESIDENT AND CEODec 15 '25Option Exercise0.00167,3320615,085Dec 17
Kunkel Lori AnneDirectorDec 08 '25Option Exercise7.9010,00079,00084,200Dec 09
Kunkel Lori AnneDirectorDec 04 '25Option Exercise3.755,53420,75374,200Dec 05
Piscitelli DominicChief Financial OfficerOct 06 '25Sale14.5211,000159,71948,317Oct 08
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.